Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers

Cancer Science

Volumn 94, Issue 4, 2003, Pages 394-399

  Harada, Toshiyuki ^a   Ogura, Shigeaki ^c   Yamazaki, Koichi ^a   Kinoshita, Ichiro ^a   Itoh, Tomoo ^d   Isobe, Hiroshi ^e   Yamashiro, Katsushige ^e   Dosaka Akita, Hirotoshi ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAPPORO CITY GENERAL HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e HOKKAIDO CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; LUNG RESISTANCE PROTEIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN P53; VINDESINE;

CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSBRONCHIAL BIOPSY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0038824021     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01453.x     Document Type: Review

References (51)

1. Ginsberg RJ, Vokes E, Rosenzweig K. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott; 2001. p. 925-83.
2. Dingemans AMC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Poostmus PE. Topoisomerase II and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32: 117-28.
3. Sekido Y, Fong KM, Minna JD. Molecular biology of lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott; 2001. p. 917-25.
4. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-42.
5. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995: 267: 1456-62.
6. Lowe SW, Ruley HE, Jacks T, Houseman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
7. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N. Gralla R, Kris M, Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Canter Res 1995; 55: 5038-42.
8. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997; 3: 1195-200.
9. Brattstrom D, Bergqvist M, Lamberg K, Kraaz W, Scheibenflug L, Gustafsson G, Inganas M, Wagenius G, Brodin O. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol 1998; 15: 255-61.
10. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF. c-myc and bcl-2 modulates p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994; 91: 5878-82.
11. Hockenbery DM, Nunez G, Milliman C, Schreber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
12. Lu Q, Abel P, Foster CS, Lalani E. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-10.
13. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenesis: regulators of cell death. Blood 1992; 80: 879-86.
14. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJ, Pinedo HM. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-9.
15. Izquierdo MA, Scheffer GL, Flens MJ, Schemaker RH, Rome LH, Scheper RJ. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996; 19: 191-7.
16. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predicts the response to chemotherapy in lung cancer. Eur J Cancer 1998; 34: 1352-7.
17. Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, Tsuruta N, Wakamatsu K, Hara N. Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 1996; 78: 416-21.
18. Ishihara S, Minato K, Hoshino H, Saito R, Hara F, Nakajima T, Mori M. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer 1999; 26: 187-94.
19. World Health Organization. Histological typing of lung tumours. 2nd ed. Geneva: World Health Organization; 1999. p. 21-66.
20. American Joint Committee on Cancer. Lung. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1988. p. 115-22.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting the results of cancer treatment. Cancer 1981; 47: 207-14.
22. Dosaka-Akita H, Shindoh M, Fujino M, Kinoshita I, Akie K, Katoh M, Kawakami Y. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 1994; 102: 660-4.
23. Dosaka-Akita H, Katabami M, Hommura H, Fujioka Y, Katoh H, Kawakami Y. Bcl-2 expression in non-small cell lung cancer: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 1999; 56: 259-64.
24. Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995; 147: 1545-52.
25. Cox D, Snell E. Analysis of binary data. 2nd ed. London: Chapman and Hall; 1989.
26. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388-93.
27. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs. Cancer Res 1989; 49: 5870-8.
28. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
29. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
30. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991; 253: 49-53.
32. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491 -4.
33. Chiba I, Takahashi T, Nan MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minnna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5: 1603-10.
34. Harris CC, Hollstein M. Clinical implication of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-27.
35. Iggo R, Catter K, Bartek J, Lane D, Harris AD. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
36. Blagosklonny MV, El-Deiry WS. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 1998; 75: 933-40.
37. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996; 16: 3845-8.
38. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993; 106: 23-9.
39. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148: 877-87.
40. Dingemans AMC, van Ark-Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, Giaccone G. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 1996; 7: 625-30.
41. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance related protein LRP is the human major vault protein. Nat Med 1995; 1: 578-82.
42. Schroeijers AB, Scheffer GL, Flens MJ, Meijer GA, Izquierdo MA, van der Valk P, Scheper RJ. Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 1998; 152: 373-8.
43. Raajimaakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029-36.
44. Berger W, Elbling L, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term immunohistochemically detected p53 and P-glycoprotein predicts the response to chemotherapy in lung cancer. Int J Cancer 1998; 34: 1352-7.
45. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-11.
46. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-7.
47. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
48. Guinee DG Jr, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994; 102: 406-14.
49. Dingemans AMC, van Ark-Otte J, van der Valk P, Scheper RJ, Poostmus PE, Giaccone G. Expression of lung resistance-related protein (LRP) in lung cancer. Eur J Cancer 1995; 31: S28-9.
50. Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N, Kiyohara C. Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. Oncology 1999; 57: 318-23.
51. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutation, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996; 56: 206-9.